CPN1: A Potential Drug Target and Biomarker (G1369)

Target Name: CPN1

NCBI ID: G1369

CPN1

CPN1: A Potential Drug Target and Biomarker

CPN1, also known as carboxypeptidase N or polypeptide 1, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the serine proteases family 11 and is responsible for the catalytic breakdown of peptides that contain carboxylic acids.

CPN1 is a potential drug target and has been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique mechanism of action and its expressed expression in a variety of tissues make it an attractive target for drug development.

The discovery and characterization of CPN1

CPN1 was first identified in the late 1980s by researchers at the University of California, Berkeley. They demonstrated that CPN1 was a highly conserved protein that was expressed in a variety of tissues, including brain, heart, liver, and muscle. They also found that the catalytic active site of CPN1 was unique and was specific for the breakdown of carboxylic acids.

Since then, several studies have confirmed the importance of CPN1 in various physiological processes. For example, studies have shown that CPN1 is involved in the regulation of inflammation, immune response, and tissue repair. It has also been shown to play a role in the development and progression of cancer.

CPN1 as a drug target

CPN1 has been identified as a potential drug target due to its unique mechanism of action and its expressed expression in a variety of tissues. CPN1 functions as a serine proteases, which means it breaks down other proteins into their component amino acids. This unique mechanism of action makes it an attractive target for drugs that can inhibit its activity.

One of the main advantages of targeting CPN1 is its expression in a variety of tissues, which makes it less likely to have unintended consequences in other parts of the body. Additionally, CPN1 is a protein that is expressed in most tissues and is highly conserved, which makes it easier to develop targeted inhibitors.

CPN1 has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that inhibiting CPN1 can inhibit the development of cancer in animal models. Additionally, CPN1 has has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease, and has been shown to play a role in the development of autoimmune disorders, such as rheumatoid arthritis.

CPN1 as a biomarker

CPN1 has also been identified as a potential biomarker for several diseases. Its unique mechanism of action and its expressed expression in a variety of tissues make it an attractive target for the development of diagnostic tests.

For example, CPN1 has been shown to be expressed in a variety of tissues and has been used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Studies have shown that the expression of CPN1 is associated with the development of these diseases and that inhibiting CPN1 can be an effective way to diagnose and treat these diseases.

Conclusion

CPN1 is a unique and promising protein that has been identified as a potential drug target and biomarker for several diseases. Its mechanism of action and its expressed expression in a variety of tissues make it an attractive target for drug development and diagnostic testing. Further research is needed to fully understand the role of CPN1 in these diseases and to develop effective treatments.

Protein Name: Carboxypeptidase N Subunit 1

Functions: Protects the body from potent vasoactive and inflammatory peptides containing C-terminal Arg or Lys (such as kinins or anaphylatoxins) which are released into the circulation

The "CPN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets